R
Raquel Bengió
Researcher at Academia Nacional de Medicina
Publications - 41
Citations - 902
Raquel Bengió is an academic researcher from Academia Nacional de Medicina. The author has contributed to research in topics: Myeloid leukemia & Population. The author has an hindex of 10, co-authored 41 publications receiving 810 citations.
Papers
More filters
Journal ArticleDOI
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Journal ArticleDOI
Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Carolina Bárbara Belli,Susana Acevedo,Raquel Bengió,Guillermo Arrossagaray,Nora Watman,Norma Rossi,Juan Luis García,Gabriela Flores,Sofia Goldztein,Irene Larripa +9 more
TL;DR: The aim of this study was to evaluate the application of the IPSS in the Argentine population, to test the prognostic value of its variables and to determine whether this score helps to associate prognostic subgroups of risk into FAB subtypes.
Journal ArticleDOI
Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia
TL;DR: Hairy cell leukemia patients in complete remission may have minimal residual disease (MRD), and flow cytometry and immunohistochemistry performed to detect MRD did not predict relapse.
Journal ArticleDOI
Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients
Carolina Bárbara Belli,Raquel Bengió,Pedro Negri Aranguren,Francisco Sakamoto,María Gabriela Flores,Nora Watman,Elsa Nucifora,Maria Virginia Prates,Jorge Arbelbide,Irene Larripa +9 more
TL;DR: It can be concluded that all isolate deletions (excluding 7q‐) are good prognostic findings and all monosomies (excluding Y chromosome loss) are bad indicators.
Journal ArticleDOI
Cytogenetic and molecular studies of variant Ph' translocations
TL;DR: The limits between MDS and myeloproliferative syndromes as well as truly acute non-lymphoblastic leukemias with myelodysplasia seem to be indistinct and new entities could be defined provided that nonrandom chromosomal abnormalities can be demonstrated in these patients.